A graduate student from the University of Wisconsin–Madison is pushing for the disaggregation of data in research to better understand how individuals from different ethnic subgroups are represented as research participants and as researchers. Kao Lee Yang began writing and discussing the topic after the Howard Hughes Medical Institute’s Gilliam Fellowship for Advanced Study rejected her application for not meeting their racial and ethnic underrepresentation criteria, despite often being the only Hmong American scientist in many research spaces. Yang joins the podcast to discuss her opinion piece for STAT News, the problems with using aggregated data, and how the push to study individual ethnic groups could improve Alzheimer’s disease research.
Guest: Kao Lee Yang, MPA/PhD candidate in the Neuroscience and Public Policy Program and Bendlin Laboratory, University of Wisconsin–Madison
Episode Topics6:12 Why is combining all Asian people into one category detrimental? What is improved when this population is broken down by specific heritages and ethnicities?
8:40 How did people respond to your initial article in STAT News?
9:30 Why do you think it’s important to look at the individual ethnic groups within research?
11:17 How does the problem of aggregating data on Asian Americans impact the field of Alzheimer’s disease research?
Show NotesRead Yang’s opinion piece, “I’m almost always the only Hmong American scientist in the room. Yet I was told I come from a group overrepresented in STEM,” on STAT News’ website.
Read Yang’s correspondence, “Disaggregate data on Asian Americans — for science and scientists,” on Nature’s website.
To learn about more Hmong researchers and scientists like Kao Lee Yang, follow the Twitter account she recently launched, @HmongInBioSci.
Read about Alzheimer’s disease research in the Bendlin Lab.
Putting Lecanemab into Practice: A Clinician’s Perspective on the New Alzheimer’s Treatment
Deciding to Donate: Barriers and Benefits of Brain Donations for Diverse Populations
Lecanemab, Clinical Trials, and the Importance of Clinical Meaningfulness
Understanding the Social Determinants of Health and Disparities in Alzheimer’s Research
Take Care of Your MIND: Reviewing the MIND Diet for Healthy Brain Aging
The National Strategy for Diversifying Alzheimer’s Research
The Future of Neuroscience: Early-Career Researchers Named ’One to Watch’ by the Alzheimer’s Association
Studies Look at Generational Differences and Associations between Cognition, Sensory Changes and Blood Biomarkers
Disclosing Alzheimer’s Disease Biomarker Results in Diverse Populations
Difficult but Beneficial Conversations about End-of-Life Care
Caregiving While Black: Dementia Care for Different Racial and Ethnic Groups
Our Evolving Understanding of Mild Cognitive Impairment
A Closer Look at the Lecanemab Clinical Trials
Therapeutic Fibbing: Mastering the Art of Communicating with a Loved One with Dementia
The Future of the Alzheimer’s Association: Interview with Dr. Joanne Pike and Harry Johns
Introducing Lecanemab, the Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval
Healthy Habits for the New Year and Modifiable Risk Factors for Alzheimer’s Disease
Bioenergetics: How Mitochondria Affects Alzheimer’s Disease and Aging
Looking Toward the Future: How Preclinical Alzheimer’s Disease Biomarker Disclosures Impact Society
Mixed Dementia, Explained
Create your
podcast in
minutes
It is Free
Life in the A-Zone
Caregiver Storyteller - About Alzheimer’s and Dementia Caregiving
The Life, Love, and Alzheimer’s Podcast
Fading Memories: Alzheimer’s/Dementia Caregiver Support
Alzheimer’s Speaks